In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic's bifurcation stent starts human trial

This article was originally published in Clinica

Executive Summary

A drug-eluting bifurcation stent could be on the horizon. Medtronic has initiated the first human trial of a non-drug-coated branched stent, results of which will determine whether it will begin developing a drug-eluting version. The safety and deliverability of the stent is being assessed in a 60-patient study called BRANCH, based in Australia and New Zealand. Primary endpoints include cardiac death, myocardial infarction involving the target vessel, and target vessel revascularisation (TVR) 30 days post-implant. Patient enrolment is expected to be complete by the end of 2008, with results available early in 2009.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts